Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Hans Schomerus"'
Publikováno v:
Journal of Hepatology. 34:768-773
Autor:
Wolfgang Hamster, Hans Schomerus
Publikováno v:
Metabolic Brain Disease. 16:37-41
Minimal hepatic encephalopathy (HE) is a major cause of premature retirement in cirrhotics. The decision on the earning capability of a patient is usually based on clinical judgement, considering the patient's complaints and clinical findings such as
Autor:
Alfred Hellstern, Ulrich Leuschner, Ala Benjaminov, Hanns Ackermann, Thomas Heine, Davide Festi, Monica Orsini, Enrico Roda, Tim C. Northfield, Riadh Jazrawi, Winfried Kurtz, Hans Joachim Schmeck-Lindenau, Jochen Stumpf, Britt E. Eidsvoll, Erling Aadland, Gerd Lux, Eckhart Boehnke, Ditmar Wurbs, Myriam Delhaye, Michel Cremer, Ingolf Sinn, Erich Horing, Ulrich V. Gaisberg, Michael Neubrand, Tilmann Sauerbruch, Vladimir Salamon, Werner Swobodnik, Hasko V. Sanden, Wolfgang Schmitt, Thomas Kaser, Hans Schomerus, Johannes Georg Wechsler, Paul Janowitz, Jorn Lohmann, Heiner Porst, Adolfo Francesco Attili, Eberhard Bartels, Wolfgang Arnold Wolf, Dieter Strohm, Fred Paul
Publikováno v:
Digestive Diseases and Sciences. 43:911-920
Since there are now several ways to treat symptomatic gallstone disease, one is able to select treatment on the basis of the patient's comfort, the practicability, effectiveness, and side effects of the technique, and the relative costs. In order to
Publikováno v:
Hepatology. 4:15-19
Two immunosuppressive serum factors, serum inhibition factor (SIF) and rosette inhibitory factor (RIF), were studied in sera from patients with acute and chronic viral hepatitis. In a study of 30 patients with acute viral hepatitis, an association wa
Autor:
Hans Schomerus
Publikováno v:
Theology. 50:123-129
Autor:
Hans Schomerus
Publikováno v:
Jahrbuch der Raabe-Gesellschaft. 9:41-48
Autor:
Hans Schomerus
Publikováno v:
Jahrbuch der Raabe-Gesellschaft. 3:32-46
Autor:
Hans Schomerus
Publikováno v:
Jahrbuch der Raabe-Gesellschaft. 6:49-57
Autor:
Georg Strohmeyer, Hans K. Dürr, Wolfram Gerlich, Christian Bode, Harald Goebell, André L. Blum, Klaus Dietz, Karl H. Wiedmann, Gert Frösner, Peter A. Berg, Hans Schomerus, Wolfgang Dölle, Klaus Balzer, Herrmann Peerenboom
Publikováno v:
Hepatology (Baltimore, Md.). 4(2)
One-hundred sixty patients (81 cyanidanol, 79 placebo) were included in a double-blind placebo-controlled clinical trial to evaluate the effect of 3 gm (+)-cyanidanol-3 per day for 8 weeks on the clinical course of acute viral hepatitis and HBsAg eli